Additional Precautions for Clinical Syndromes and Conditions

Site Applicability

PHC Acute and Long Term Care Sites

Practice Level

Basic: Physicians, NPs, Nursing, Clinical Nurse Leader, Clinical Site Coordinator, Bed Placement Coordinator

Standards

In addition to Routine Practices, <u>Additional Precautions</u> will be applied for clinical syndromes and conditions deemed potentially infectious even prior to a diagnosis being made.

A risk assessment for potentially infectious clinical syndromes and conditions will be completed on admission for **all inpatient acute care admissions** using the *Infectious Disease Risk Screening* (IDRS) PowerForm in Cerner (the same form used to <u>screen for antibiotic resistant organisms</u>).

Guideline

Patients may present to hospital with clinical syndromes and conditions deemed potentially infectious that require immediate implementation of <u>Additional Precautions</u>, often prior to a diagnosis being made (e.g., meningitis, viral gastroenteritis, and measles). Additional Precautions are also designed to prevent transmission of emerging or rare illnesses such as avian influenza, Severe Acute Respiratory Syndrome (SARS), and hemorrhagic fever for which there is frequently a delay in diagnosis.

Patients presenting with the following clinical syndromes or conditions should be considered for Additional Precautions until a diagnosis is made, after which the need for precautions should be reassessed. These general recommendations are not meant to replace clinical judgment.

- Draining wound = Contact Precautions
- Infestation = Contact Precautions
- Diarrhea (new onset) = Contact Plus Precautions
- Stiff neck, photophobia, fever, and headache = Droplet Precautions
- Acute cough, fever, malaise, shortness of breath = Droplet and Contact Precautions
- Fever with rash = Airborne Precautions
- Hemoptysis, unexplained weight loss, night sweats = Airborne Precautions
- Disseminated vesicular rash and fever = Airborne and Contact Precautions

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 20/OCT/2022 Page 1 of 5



Assessment, Intervention, and Documentation

- The IDRS PowerForm (see <u>Appendix A</u>) will be included in the admission order set for all acute care inpatient admissions.
 - IDRS can be a separate PowerForm or be embedded in other PowerForms (e.g., ED Triage – Adult PowerForm, OB Triage and Assessment PowerForm, MH Initial Admission PowerForm, etc).
- Answering "Yes" to any of these IDRS questions will trigger an automatic order for the appropriate Additional Precautions which will be displayed in the banner bar.

IDRS Documentation with "Yes" Response	Automated Patient Isolation Orders Placed by Cerner
Suspected Viral Respiratory Infection: acute onset fever WITH shortness of breath or cough	Droplet and Contact
Suspected Infectious Diarrhea: acute onset of diarrhea	Contact Plus
Suspected Infectious Vomiting: acute onset of vomiting	Droplet and Contact
Fever with Headache, Photophobia, or Alternated Level of Consciousness (e.g. Meningitis)	Droplet
Fever with Rash (e.g. Measles)	Airborne
Fever with Parotid Swelling (e.g. Mumps)	Droplet and Contact
Query TB (e.g. Hemoptysis)	Airborne
Vesicular Rash (e.g. Shingles, Chickenpox)	Contact (if immune-competent with localized rash) OR Airborne and Contact (if immunocompromised patient or patient with disseminated rash or facial rash)

- The most responsible nurse will ensure the appropriate Additional Precaution sign is posted on the door.
- Admitted patients who develop signs and symptoms compatible with an infectious syndrome
 or condition in the period after admission should be placed on the appropriate Additional
 Precaution (i.e., ordered in Cerner and precaution sign posted on door) and the most
 responsible physician should be notified.

Patient Placement

- Routine Practices and Point of Care Risk Assessment are used in the routine care of all patients at all times in all healthcare settings and are determined by the circumstances of the patient, the environment and the task to be performed.
- Patients with a clinical syndrome or condition that warrants <u>Airborne</u> or <u>Airborne</u> and <u>Contact</u>
 <u>Precautions</u> must be placed in a private, negative pressure airborne infection isolation room.

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 20/OCT/2022 Page 2 of 5



 Refer to the <u>Patient Placement Guidelines</u> for further information on private room prioritization.

Related Documents

Additional Precautions

- B-00-07-13084 Airborne and Contact Precautions Infection Control
- B-00-07-13028 Airborne Precautions Infection Control
- B-00-07-13074 Contact Plus Precautions Infection Control
- <u>B-00-07-13029</u> Contact Precautions Infection Control
- ▶ <u>B-00-07-13079</u> Droplet and Contact Precautions Infection Control
- B-00-07-13030 Droplet Precautions Infection Control

Other Documents

- <u>B-00-07-13001</u> Antibiotic Resistant Organisms Screening Acute Care
- <u>B-00-07-13087</u> Patient Placement Guidelines Infection Control
- B-00-07-13081 Point of Care Risk Assessment IPAC Best Practice Guideline
- B-00-07-13045 Routine Practices Infection Control
- CST Cerner Help Document Infectious Disease Risk Screening

References

Centers for Disease Control and Prevention. (2022). 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. Retrieved from https://www.cdc.gov/infectioncontrol/pdf/guidelines/isolation-guidelines-H.pdf

Public Health Agency of Canada. (2017). Routine Practices and Additional Precautions for Preventing the Transmission of Infection in Healthcare Settings. Retrieved from

https://www.canada.ca/en/public-health/services/publications/diseases-conditions/routine-practices-precautions-healthcare-associated-infections.html

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 20/OCT/2022 Page 3 of 5



Appendix A: Infectious Disease Risk Screening PowerForm

More information on how to fill out the Infectious Disease Risk Screening PowerForm can be found at <u>CST Cerner Help</u>.

Refer to field reference text (right-click		creeni					
Confirm all automated orders are consi	on field) stent wit) for automa th site-speci	ated isoli fic guide	ation and ARO swa lines.	b order infor	mation.	
yndromic Symptom Surveillance							
ADULTS (17 years or older): Does th	e patien	t have any	of the f	ollowing signs or	symptoms?		(Ref)
PEDS (less than 17 years): Does the	e patien	t and/or a	househo	dd member have		lowing signs o	
"Suspected Viral Respiratory Infection	No	Y	es U	Inable to obtain			
"Suspected Viral Respiratory Intection "Suspected Infectious Diarrhea		_					
Suspected Infectious Vomiting							
*Fever with H/A, Photophobia, or Alt LOC							
"Fever with Rash (e.g. Measles)							
*Fever with Parotid Swelling (e.g. Mumps)							
"Query TB (e.g. Hemoptysis)							
"Vesicular Rash (e.g Shingles,Chickenpox)						
Vesicular Rash Description (Ref) Immunocompromised patient Localized in			sseminated		cial rash		
Intibiotic Resistant Organism (AR During the past YEAR, has the patien	t experi					In which Cana	ndian facility did this
antibiotic-resistant organism risk fac	tors?	-	-			nearthcare or	curr
None		Incarcera					
Canadian healthcare (invasive procedure, over				with known CPO			
Chemotherapy (invasive, intravenous or intrath	ecal)			with known MRSA and/	or VHE		
Dialysis Homelessness, in shelter or refugee camp		☐ Substand					
In halfway/group home or long-term care facilit		Unable to	Occari				
In narway/group nome or long-term care racing	<i>r</i>						
Does the patient have a history of ar	y of the	following?	(Ref)			ARO History	Details (Ref)
		lo	Yes	Unable to obtain		C. Auris	☐ Other/unknown
"History of AROs	-		100	Crimanic to options		□ CPO	
"Healthcare OUTSIDE Canada in Last Yes	M					☐ MRSA	
*Recent Exposure to Communicable Disea	se					□ VRE	
"Recent Exposure to Communicable Disea	se					_	
"Recent Exposure to Communicable Disea In which facility and/or country did this foreign healthcare occur?	When di	id this forei		Communicable Disc	ease (Ref)	_	
In which facility and/or country	When di					VRE	
In which facility and/or country	When di healthca	are occur?	ys [xposed To:	jes Mu	VRE	
In which facility and/or country	When di healthca	are occur? the last 21 day	70 E	xposed To: Chickenpox or shing	jes Mu	WRE WRE	
In which facility and/or country	When di healthca	are occur? the last 21 day than 21 days ay	70 E	xposed To: Chickenpox or shing Confirmed COVID-15	fes Mu 3 patient Tul	WRE WRE	
In which facility and/or country	When di healthci O Within O More I O Unabi	are occur? the last 21 day than 21 days ay	70 E	xposed To: Chickenpox or shing Confirmed COVID-15	fes Mu 3 patient Tul	WRE WRE	
In which facility and/or country did this foreign healthcare occur?	When di healthca O Within O More I O Unabli	are occur? I the last 21 day than 21 days ag le to obtain	ys go	Chickenpox or shing Confirmed COVID-1: Measles	gles Mu B patient Tul Oth	mpo berculosis ser:	
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re	When di healthca Within More I Unabli	are occur? I the last 21 day than 21 days ag le to obtain	ys go	xposed To: Chickenpox or shing Confirmed COVID-15	gles Mu B patient Tul Oth	mpo berculosis ser:	
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re	When di healthca C Within C More I C Unabli	are occur? In the last 21 day than 21 days ay is to obtain atment pleted treatmen	ys [Exposed To: Chickenpox or shing Confirmed CDVID-19 Measles Treated - did not com Unable to obtain	jies Mu 3 patient Tu 0th	mps berculosis ser:	
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re N/A Re Active pulmonary T8 Tre	When di healthca C Within C More I C Unabli ceiving bea	are occur? In the last 21 day than 21 days ay is to obtain atment pleted treatmen	ys [cxposed To: Chickenpox or shing Confirmed CDVID-19 Measles Treated - did not com Unable to obtain	ples Mu Papalierik Tul	mps beroulosis see:	
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re N/A Re Active pulmonary T8 Tre	When di healthca C Within C More I C Unabli ceiving bea	are occur? In the last 21 day than 21 days ay is to obtain atment pleted treatmen	ys [cxposed To: Chickenpox or shing Confirmed CDVID-19 Measles Treated - did not com Unable to obtain	ples Mu Papalierik Tul	mps berculosis sec: Other: the field below to the patient/hou	
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re N/A	When di healthca C Within C More I C Unabli ceiving bea	are occur? In the last 21 day than 21 days ay the to obtain atment pleted treatmen Location o	ys [Chickenpox or shing Confirmed CDVID-19 Measles Treated - did not com Unable to obtain Travel If needed specific of	plete treatment	mps berculosis sec: Other: the field below to the patient/hou	
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re N/A Re Active pulmonary TB Tre Have you or a household member traoutside of Canada within the last 30	When di healthca C Within C More I C Unabli ceiving bea	are occur? In the last 21 day than 21 days ay is to obtain atment pleted treatmen Location o Atrica Asia	go E	Chickenpox or shing Chickenpox or shing Confirmed CDVID-19 Measiles Treated - did not com Unable to obtain Travel If needed specific of China	plete treatment	mps beroulosis her: Other: the field below to the patient/houssia	o comment on the sehold member traveled
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re N/A Re Active pulmonary T8 Technology T9 Technology	When di healthca C Within C More I C Unabli ceiving bea	are occur? In the last 21 day than 21 days ay is to obtain atment pleted treatmen Location o Atrica Asia	ys go [go]	Chickenpox or shing Chickenpox or shing Confirmed CDVID-19 Measles Treated - did not com Unable to obtain Travel If needed specific of China Eastern Europe	plete treatment	mps berculosis see: Other: the field below to the patient/houssia with America	
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re N/A Re Active pulmonary TB Tre Have you or a household member tra outside of Canada within the last 30 Yes, paient Yes, household member	When di healthca C Within C More I C Unabli ceiving bea	are occur? In the last 21 day than 21 days ay is to obtain atment pleted treatmen Location o Asia Asia Asia	ys go []	Chickenpox or shing Chickenpox or shing Confirmed CDVID-15 Measiles Treated - did not com Unable to obtain Travel If needed specific of China Eastern Europind India	plete treatment	mps berculosis ser: Other: the field below to the patient/housesia with America ited States estern Europe	
In which facility and/or country did this foreign healthcare occur? Tuberculosis Status Description (Re	When di healthca C Within C More I C Unabli ceiving bea	are occur? In the last 21 days ay then 21 days ay the to obtain atment pleted treatment Location o Asia Australia/ Caribbear	ys go []	Chickenpox or shing Confirmed CDVID-19 Measiles Treated - did not com Unable to obtain Travel If needed specific of China Eastern Europend India Mesico	plete treatment	mps berculosis ser: Other: the field below to the patient/housesia with America ited States estern Europe	

This material has been prepared solely for use at Providence Health Care (PHC). PHC accepts no responsibility for use of this material by any person or organization not associated with PHC. A printed copy of this document may not reflect the current electronic version.

Effective date: 20/OCT/2022 Page 4 of 5



First Released Date:	17-SEP-2008
Posted Date:	20-OCT-2022
Last Revised:	20-OCT-2022
Last Reviewed:	20-OCT-2022
Approved By:	PHC
(committee or position)	IPAC Standards Committee
Owners:	PHC
(optional)	IPAC

Effective date: 20/OCT/2022 Page 5 of 5